001     287265
005     20250512114324.0
024 7 _ |a 10.1007/s11060-023-04547-5
|2 doi
024 7 _ |a pmid:38253790
|2 pmid
024 7 _ |a 0167-594X
|2 ISSN
024 7 _ |a 1573-7373
|2 ISSN
024 7 _ |a altmetric:158649899
|2 altmetric
037 _ _ |a DKFZ-2024-00197
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Obrecht-Sturm, Denise
|0 0000-0002-3216-8452
|b 0
245 _ _ |a Pineal anlage tumor: clinical and diagnostic features, and rationales for treatment.
260 _ _ |a Dordrecht [u.a.]
|c 2024
|b Springer Science + Business Media B.V
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1713786210_20489
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Jan;166(2):359-368
520 _ _ |a To provide a treatment-focused review and develop basic treatment guidelines for patients diagnosed with pineal anlage tumor (PAT).Prospectively collected data of three patients with pineal anlage tumor from Germany was combined with clinical details and treatment information from 17 published cases.Overall, 20 cases of PAT were identified (3 not previously reported German cases, 17 cases from published reports). Age at diagnosis ranged from 0.3 to 35.0 (median: 3.2 ± 7.8) years. All but three cases were diagnosed before the age of three years. For three cases, metastatic disease at initial staging was described. All patients underwent tumor surgery (gross-total resection: 9, subtotal resection/biopsy: 9, extent of resection unknown: 2). 15/20 patients were alive at last follow-up. Median follow-up for 10/15 surviving patients with available follow-up and treatment data was 2.4 years (0.3-6.5). Relapse was reported for 3 patients within 0.8 years after diagnosis. Five patients died, 3 after relapse and 2 from early postoperative complications. Two-year-progression-free- and -overall survival were 65.2 ± 12.7% and 49.2 ± 18.2%, respectively. All 4 patients who received intensive chemotherapy including high-dose chemotherapy combined with radiotherapy (2 focal, 2 craniospinal [CSI]) had no recurrence. Focal radiotherapy- and CSI-free survival rates in 13 evaluable patients were 46.2% (6/13) and 61.5% (8/13), respectively.PAT is an aggressive disease mostly affecting young children. Therefore, adjuvant therapy using intensive chemotherapy and considering radiotherapy appears to comprise an appropriate treatment strategy. Reporting further cases is crucial to evaluate distinct treatment strategies.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a PINEAL anlage tumor
|2 Other
650 _ 7 |a Pineal gland
|2 Other
650 _ 7 |a Pineoblastoma
|2 Other
700 1 _ |a Pfaff, Elke
|0 P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb
|b 1
|u dkfz
700 1 _ |a Mynarek, Martin
|b 2
700 1 _ |a Bison, Brigitte
|b 3
700 1 _ |a Rodehüser, Martina
|b 4
700 1 _ |a Becker, Martina
|b 5
700 1 _ |a Kietz, Silke
|b 6
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 7
|u dkfz
700 1 _ |a Jones, David T
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 8
|u dkfz
700 1 _ |a Sturm, Dominik
|0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
|b 9
|u dkfz
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 10
|u dkfz
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 11
|u dkfz
700 1 _ |a Kortmann, Rolf-Dieter
|b 12
700 1 _ |a Schwarz, Rudolf
|b 13
700 1 _ |a Pietsch, Torsten
|b 14
700 1 _ |a Fleischhack, Gudrun
|b 15
700 1 _ |a Rutkowski, Stefan
|b 16
773 _ _ |a 10.1007/s11060-023-04547-5
|0 PERI:(DE-600)2007293-4
|n 2
|p 359-368
|t Journal of neuro-oncology
|v 166
|y 2024
|x 0167-594X
856 4 _ |u https://inrepo02.dkfz.de/record/287265/files/s11060-023-04547-5.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/287265/files/s11060-023-04547-5.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:287265
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-20
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-20
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-20
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEURO-ONCOL : 2022
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-20
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-20
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pädiatrische Gliomforschung
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21